Ask AI
ProCE Banner Activity

Expert Thoughts on Integrating Subcutaneous Immune Checkpoint Inhibitor Therapy Into the Care of Patients With Solid Tumors

Clinical Thought

Read this commentary with our thoughts on integrating subcutaneous immune checkpoint inhibitor therapy into the care of patients with cancer, including the latest pharmacokinetics, efficacy, and safety data in patients with NSCLC, RCC, and melanoma, with examples on how to incorporate these results into everyday practice.

Released: May 23, 2025

Expiration: November 22, 2025

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, LLC and ProCE, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Partners

Practicing Clinicians Exchange, LLC

ProCE Banner

ProCE, LLC

ProCE Banner

Disclosure

Primary Author

Patrick Forde, MD, PhD: researcher (paid to institution): AstraZeneca, BioNTech, Bristol Myers Squibb, Novartis, Regeneron; consultant: Amgen, Ascendis, AstraZeneca, BioNTech, Bristol Myers Squibb, Curevac, G1, Genelux, Genentech, Gritstone, F Star, Flame, Fosun, Iteos, Janssen, Merck, Novartis, Regeneron, Sanofi, Synthekine, Tavotek, Teva.

Saby George, MD, FACP: consultant/advisor/speaker: AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Exelixis, GlaxoSmithKline, Jonnson & Johnson, Merck Sharp & Dohme, Novartis.

Evan J. Lipson, MD: consultant/advisor/speaker: Bristol Myers Squibb, HUYA Bioscience International, Immunocore, InstilBio, IO Biotech, Merck, Merck KGaA, Novartis, OncoSec, Pfizer, Regeneron, Sun; researcher: Bristol Myers Squibb, Haystack; individual publicly traded stock/stock options: Iovance.